LSP Life Science Partners

What is LSP Life Science Partners?

EQT Life Sciences, formerly known as LSP Life Sciences Partners, is one of Europe's largest and most experienced life sciences investors. With headquarters in the Netherlands, they specialize in venture capital (VC) investments predominantly in the Seed stage. Their primary focus is on life sciences companies developing innovative therapeutics, medical devices, diagnostics, and healthcare technology on a global scale.

Comprising a team of seasoned investment professionals with medical, scientific, and industry expertise, they aim to provide not only capital but also strategic, clinical, operational, financial, and commercial guidance and support to inventors working on transformative healthcare solutions.

EQT Life Sciences believes in making a significant impact by converting cutting-edge scientific innovations into real-world applications that improve patient outcomes, targeting areas with high unmet medical needs.Through a history spanning 30 years and 12 funds, EQT Life Sciences has raised approximately 3.5 billion euros, investing in over 150 private companies.

They pursue investment opportunities in a variety of sectors, with particular emphasis on drug development at all stages through their Life Sciences Funds (LSP 1-7), later-stage MedTech, Digital Health, and Diagnostics through their Health Economic Funds aimed at enhancing care quality and lowering healthcare costs, and the Dementia Fund focusing on drug development and technology for neurodegenerative diseases.EQT Life Sciences is deeply invested in addressing demographic trends, including the growing and aging population and the increasing prevalence of lifestyle-related diseases.

They track levels of innovation, particularly in Europe, to find favorable investment opportunities created by strong science and relative capital scarcity in comparison to the US.

They monitor market momentum, expecting further growth in M&A activity within Life Sciences due to the substantial revenue risks faced by Big Pharma over the next decade.The firm's robust portfolio includes companies like Amolyt Pharma, which is dedicated to treating rare endocrine disorders; Neuravi, known for its stroke treatment technology; and Onera Health, innovating in sleep diagnosis.

To foster access to fresh ideas and opportunities, EQT Life Sciences encourages entrepreneurs to engage with them and submit investment opportunities for consideration.